Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Indivior loses U.S. district court battle, copycat launches imminent

Generic competitors to British drugmaker Indivior Plc’s blockbuster opioid addiction treatment are on course to launch after the firm’s attempt to stay a U.S. District court judgement was rejected.

Read More »

Edward Lifesciences pays Boston Scientific $180 million to end patent row

Edwards Lifesciences Corp. paid rival Boston Scientific Corp. $180 million as part of a settlement to end long-standing patent disputes between the two medical device makers.

Read More »

Ironwood and Allergan Announce Settlement with Mylan Resolving Linzess Patent Litigation

Ironwood Pharmaceuticals Inc. and Allergan plc announced that the companies reached an agreement with Mylan Pharmaceuticals Inc. resolving patent litigations brought in response to Mylan’s abbreviated new drug applications seeking approval to market generic versions of Linzess (linaclotide) before the expiration of the companies’ applicable patents.

Read More »

Boston Scientific Exercises Option to Buy Millipede

Boston Scientific exercised the company’s option to buy the remaining shares of Santa Rosa, Calif.-based Millipede for $325 million.

Read More »

Orexo soars after winning opioid drug appeal against Teva

A U.S. appeals court revived Swedish pharmaceutical company Orexo AB’s lawsuit accusing a unit of Israel’s Teva Pharmaceutical Industries Ltd. of infringing a patent for the opioid addiction drug Zubsolv.

Read More »

Indivior: U.S. court rules against generic rival’s appeal

Indivior Plc notched a legal victory after a U.S. court reaffirmed that a generic rival could not re-launch cheaper versions of the British drugmaker’s best-selling opioid addiction treatment in the United States.

Read More »

U.S. court expedites Indivior rival’s appeal to re-launch generic drug

Indivior said a U.S. court expedited a generic rival’s appeal against a preliminary injunction that blocked the sale of a copycat version of the British drugmaker’s blockbuster opioid addiction treatment.

Read More »

U.S. court rejects Allergan bid to shield patents through tribe deal

A U.S. appeals court rejected a novel strategy adopted by drug company Allergan to shield patents from review by an administrative court by transferring them to a Native American tribe.

Read More »

FDA Clears Sun Pharma’s Yonsa for Prostate Cancer

Sun Pharmaceutical Industries received approval from the U.S. Food and Drug Administration for Yonsa (abiraterone acetate) to treat metastatic castration-resistant prostate cancer.

Read More »

Akorn sues Fresenius over deal termination

U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $4.75 billion takeover agreement.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom